Medicover AB (publ) (MCVEY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Medicover AB (publ) (MCVEY) trades at $16.55 with AI Score 49/100 (Grade C). Medicover AB (publ) is a Sweden-based healthcare and diagnostic services provider operating across Europe and India. Market cap: $2.50B, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for MCVEY: MCVEY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MCVEY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MCVEY: the 1 perspectives are evenly split.
How is this calculated? →Medicover AB (publ) (MCVEY) Healthcare & Pipeline Overview
Medicover AB (publ) delivers healthcare and diagnostic solutions across Europe and India, operating clinics, hospitals, and laboratories. With a focus on both corporate and private clients, Medicover distinguishes itself through its integrated service offerings and geographic diversification in the medical care facilities sector, marked by a P/E ratio of 37.15.
What Is the Investment Thesis for MCVEY?
Medicover AB presents a mixed investment thesis. The company's diversified service offerings and geographic presence provide resilience and growth opportunities. Medicover's P/E ratio of 37.15 suggests a premium valuation, reflecting investor expectations of future growth. A dividend yield of 0.70% offers a modest income stream. Growth catalysts include expansion in emerging markets and increased demand for diagnostic services. Potential risks include regulatory changes in healthcare and economic fluctuations in its operating regions. Investors should monitor Medicover's ability to maintain profitability and manage its debt levels while capitalizing on growth opportunities.
Based on FMP financials and quantitative analysis
MCVEY Key Highlights
- Market capitalization of $2.50B, reflecting its significant presence in the healthcare sector.
- P/E ratio of 37.15, indicating investor expectations for future earnings growth.
- Profit margin of 3.3%, highlighting the company's ability to generate profit from its revenue.
- Gross margin of 23.2%, showcasing the efficiency of its service delivery and cost management.
- Dividend yield of 0.70%, providing a modest return to shareholders.
Who Are MCVEY's Competitors?
MCVEY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BVNKF Bavarian Nordic A/S | $27.80 | +0.40% | $2.14B | 52 |
| BVNRY Bavarian Nordic A/S | $9.75 | +1.51% | $2.26B | 50 |
| GGNDF GN Store Nord A/S | $14.35 | +7.17% | $2.09B | 41 |
| HYPMY Hypera S.A. | $4.05 | -2.76% | $2.85B | 45 |
| JXFGF Jinxin Fertility Group Limited | $1.00 | +244.83% | $2.56B | 49 |
| HWAIF Healwell AI Inc. | $0.53 | -3.52% | $160.75M | 65 |
| ASSF Assisted 4 Living, Inc. | $1.00 | +0.00% | $45.35M | 63 |
| FTRP Field Trip Health Ltd. | $0.84 | +1.07% | $9.81M | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MCVEY's Key Strengths?
- Diversified service offerings across healthcare and diagnostics.
- Extensive geographic presence in Europe and India.
- Strong relationships with corporate clients.
- Integrated network of clinics, hospitals, and laboratories.
What Are MCVEY's Weaknesses?
- Relatively low profit margin compared to industry peers (3.3%).
- Exposure to regulatory changes in multiple countries.
- Dependence on economic conditions in its operating regions.
- Potential for increased competition in the healthcare market.
What Could Drive MCVEY Stock Higher?
- Expansion of diagnostic services in emerging markets, driven by increased healthcare spending.
- Development and launch of new telemedicine services to improve patient access and convenience.
- Potential strategic acquisitions to expand geographic footprint and service offerings.
- Growth in corporate health programs, driven by increasing awareness of employee well-being.
- Increased demand for fertility services, driven by changing demographics and lifestyle factors.
What Are the Key Risks for MCVEY?
- Economic downturns in its operating regions could reduce demand for healthcare services.
- Regulatory changes in healthcare could impact its business model and profitability.
- Increased competition from other healthcare providers could erode its market share.
- Cybersecurity risks and data breaches could damage its reputation and financial performance.
- Currency fluctuations could impact its financial results due to its international operations.
What Are the Growth Opportunities for MCVEY?
- Expansion in Emerging Markets: Medicover has a significant presence in emerging markets like Poland, Turkey, and India. These markets offer substantial growth potential due to increasing healthcare spending and rising demand for quality medical services. By expanding its network of clinics and hospitals in these regions, Medicover can tap into a large and growing customer base. The emerging markets healthcare sector is projected to grow at a CAGR of 8-10% over the next five years.
- Increased Demand for Diagnostic Services: The demand for diagnostic services is increasing due to factors such as aging populations and rising prevalence of chronic diseases. Medicover's extensive network of laboratories and blood-drawing points positions it well to capitalize on this trend. By investing in advanced diagnostic technologies and expanding its test menu, Medicover can attract more customers and increase its revenue. The global diagnostics market is expected to reach $100 billion by 2028.
- Strategic Acquisitions: Medicover can pursue strategic acquisitions to expand its geographic footprint and service offerings. By acquiring smaller healthcare providers and diagnostic companies, Medicover can quickly enter new markets and gain access to new technologies. Strategic acquisitions can also help Medicover consolidate its position in existing markets and achieve economies of scale. Medicover has a history of successful acquisitions, demonstrating its ability to integrate new businesses effectively.
- Development of Telemedicine Services: Telemedicine is becoming increasingly popular, offering patients convenient access to medical care from their homes. Medicover can develop its telemedicine services to attract more customers and improve patient satisfaction. By offering virtual consultations and remote monitoring, Medicover can expand its reach and reduce its operating costs. The telemedicine market is expected to grow at a CAGR of 20-25% over the next five years.
- Focus on Corporate Health Programs: Medicover has a strong focus on corporate health programs, providing medical services to employees of large companies. By expanding its corporate health offerings, Medicover can secure long-term contracts and generate recurring revenue. Corporate health programs are becoming increasingly popular as companies recognize the importance of employee health and well-being. Medicover can leverage its expertise in occupational health and safety to attract more corporate clients.
What Opportunities Does MCVEY Have?
- Expansion in emerging markets with high growth potential.
- Increased demand for diagnostic services due to aging populations.
- Strategic acquisitions to expand geographic footprint and service offerings.
- Development of telemedicine services to improve patient access.
What Threats Does MCVEY Face?
- Economic downturns in its operating regions.
- Increased competition from other healthcare providers.
- Regulatory changes that could impact its business model.
- Cybersecurity risks and data breaches.
What Are MCVEY's Competitive Advantages?
- Extensive network of clinics, hospitals, and laboratories provides a wide geographic reach.
- Integrated service offerings, including healthcare and diagnostic services, create synergies and cross-selling opportunities.
- Strong relationships with corporate clients provide recurring revenue streams.
- Reputation for quality medical care and diagnostic accuracy builds customer loyalty.
What Does MCVEY Do?
Founded in 1995 and headquartered in Stockholm, Sweden, Medicover AB (publ) has grown into a prominent healthcare and diagnostic services provider. The company operates through two segments: Healthcare Services and Diagnostic Services. Its Healthcare Services segment includes medical clinics, hospitals, fertility clinics, dental clinics, and gyms. The Diagnostic Services segment offers a comprehensive suite of tests, encompassing areas such as allergy diagnostics, bacteriology, clinical chemistry, haematology, histopathology, human genetics, and molecular biology. Medicover serves a diverse clientele, including corporate clients, private individuals, and public payers, across multiple countries. The company's extensive network includes 97 clinical laboratories, 733 blood-drawing points, and 26 clinics in 10 countries, along with 117 medical clinics, 20 fertility clinics, 52 dental clinics, 25 hospitals, and 25 gyms. Medicover's geographic footprint spans Germany, Sweden, Poland, Turkey, Belarus, Bulgaria, Georgia, Hungary, Serbia, Moldova, Ukraine, and India, positioning it as a key player in the European and Indian healthcare markets.
What Products and Services Does MCVEY Offer?
- Operates medical clinics and hospitals.
- Provides diagnostic services through a network of laboratories.
- Offers fertility treatments through specialized clinics.
- Provides dental care services.
- Operates gyms and fitness centers.
- Offers corporate health programs to businesses.
- Conducts a wide range of medical tests, including allergy and autoimmune diagnostics.
How Does MCVEY Make Money?
- Generates revenue from healthcare services provided at its clinics and hospitals.
- Earns income from diagnostic tests performed at its laboratories.
- Receives payments from corporate clients for employee health programs.
- Collects fees from patients and public payers for medical services.
What Industry Does MCVEY Operate In?
Medicover operates in the growing healthcare services and diagnostics market. The industry is driven by factors such as aging populations, increasing prevalence of chronic diseases, and technological advancements in diagnostics. The competitive landscape includes both large multinational corporations and smaller regional players. Medicover's integrated service offerings and geographic diversification provide a competitive advantage. The global healthcare market is expected to continue growing, presenting opportunities for Medicover to expand its market share and revenue.
Who Are MCVEY's Key Customers?
- Corporate clients seeking healthcare services for their employees.
- Private individuals seeking medical care and diagnostic testing.
- Public payers, such as government healthcare systems.
- Patients seeking fertility treatments and dental care.
Medicover AB (publ) (MCVEY) Valuation Context
Valued at $2.50B, MCVEY is classified as a mid-cap stock. Relative to its peer group, MCVEY's quantitative score of 49/100 is roughly in line with the peer average of 47/100.
ROE 15%Key Financial Metrics
Return on equity for Medicover AB (publ) stands at 15.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.3%, showing how much profit it generates from its asset base. MCVEY trades at a trailing price-to-earnings ratio of 40.11, above the Healthcare sector average of ~23x. Its free cash flow yield is 5.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.74 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 2.5%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 5/9Financial Health
Medicover AB (publ)'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.93 places it in the grey zone, a middle ground that warrants monitoring.
FY2026 estForward Outlook
Wall Street analysts project Medicover AB (publ) revenue of about $2.66B for fiscal 2026, with EPS near $0.00. The estimate reflects 6 contributing analysts.
MCVEY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Diversified service offerings across healthcare and diagnostics.
- Extensive geographic presence in Europe and India.
- Strong relationships with corporate clients.
- Integrated network of clinics, hospitals, and laboratories.
Bear Case
- Relatively low profit margin compared to industry peers (3.3%).
- Exposure to regulatory changes in multiple countries.
- Dependence on economic conditions in its operating regions.
- Potential for increased competition in the healthcare market.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
MCVEY Latest News
No recent news available for MCVEY.
MCVEY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MCVEY.
Price Targets
Wall Street price target analysis for MCVEY.
MCVEY MoonshotScore
What does this score mean?
The MoonshotScore rates MCVEY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: John Paul Stubbington
CEO
John Paul Stubbington serves as the CEO of Medicover AB (publ). Information regarding his detailed career history, education, and previous roles is not available in the provided data. As CEO, he is responsible for leading the company's strategic direction and overseeing its operations across multiple countries and business segments. His leadership is crucial for Medicover's continued growth and success in the competitive healthcare market.
Track Record: John Paul Stubbington is responsible for managing 47,000 employees. Specific achievements, strategic decisions, and company milestones under his leadership are not available in the provided data. His focus is likely on expanding Medicover's market presence, improving operational efficiency, and driving innovation in healthcare services.
Medicover AB (publ) ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. MCVEY is an ADR, allowing U.S. investors to invest in Medicover AB (publ) without directly dealing with foreign exchanges. Each MCVEY ADR represents a specific number of Medicover AB (publ)'s shares traded on the Stockholm exchange.
- Home Market Ticker: Nasdaq Stockholm, Sweden
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: MCVE
MCVEY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited financial disclosure and may not meet the listing requirements of major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the lack of regulatory oversight and potential for fraud or manipulation. Information availability is often limited, making thorough due diligence essential.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in MCVEY.
- Low trading volume and wide bid-ask spreads can make it difficult to buy or sell shares.
- Lack of regulatory oversight increases the potential for fraud or manipulation.
- Price volatility can be higher compared to stocks listed on major exchanges.
- Information availability may be limited, making due diligence challenging.
- Verify the company's financial statements and audit reports.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Determine the company's regulatory compliance status.
- Evaluate the company's liquidity and trading volume.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Medicover AB (publ) is a established healthcare provider with operations in multiple countries.
- The company has a significant number of employees (47,000).
- Medicover AB (publ) is listed on the Nasdaq Stockholm exchange.
- The company has a market capitalization of $2.50B.
- Medicover AB (publ) has been in operation since 1995.
Common Questions About MCVEY (Healthcare)
What does Medicover AB (publ) do?
Medicover AB (publ) is a healthcare and diagnostic services provider operating across Europe and India. It offers a wide range of medical services through its network of clinics, hospitals, and laboratories. The company's services include general healthcare, specialist consultations, diagnostic testing, fertility treatments, and corporate health programs. Medicover serves corporate clients, private individuals, and public payers, providing integrated healthcare solutions to meet their diverse needs. Its diagnostic services cover areas such as allergy testing, clinical chemistry, haematology, and molecular biology.
What are the main risks for MCVEY?
Medicover faces several risks, including economic downturns in its operating regions, which could reduce demand for healthcare services. Regulatory changes in healthcare could impact its business model and profitability. Increased competition from other healthcare providers could erode its market share. Cybersecurity risks and data breaches could damage its reputation and financial performance. Currency fluctuations could impact its financial results due to its international operations. Investors should carefully consider these risks before investing in MCVEY.
What are the key factors to evaluate for MCVEY?
Medicover AB (publ) (MCVEY) holds an AI score of 49/100 (low). Not financial advice.
How frequently does MCVEY data refresh on this page?
MCVEY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven MCVEY's recent stock price performance?
Medicover AB (publ) (MCVEY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified service offerings across healthcare and diagnostics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MCVEY overvalued or undervalued right now?
Valuing Medicover AB (publ) (MCVEY) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying MCVEY?
Before investing in Medicover AB (publ) (MCVEY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding MCVEY to a portfolio?
Key strength of Medicover AB (publ) (MCVEY): Diversified service offerings across healthcare and diagnostics. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data and market information are based on available sources and may be subject to change.
- The analysis is based on the provided data and does not constitute financial advice.
- OTC market data may be limited and less reliable than data from major exchanges.